Pulse Biosciences: Revolutionizing Heart & Thyroid Care

Pulse Biosciences unveiled their 2025 year-end update, showcasing their nsPFA technology for tissue treatment. They secured FDA approvals for heart catheter and surgical clamp trials for atrial fibrillation, with 250 issued and 180 pending patents. The nPulse catheter achieved impressive results in Europe, with 100% success at six months and 96% at one year. The clamps IDE trial is ongoing, aiming to enroll 136 patients. Docs are excited about the speed, safety, and durability, potentially flipping atrial fib treatment. Vybrance for thyroid nodules generated $264k in Q4 revenue, with a 50-patient study nearing completion. Pulse is positioned as the nsPFA frontrunner, with partnerships for global rollout and cash reserves of $80.7m for trials through 2026. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c92a46cb500ed99c